# University of Florida Clinical and Translational Research Building

**Year 5 Tax-Exempt Bond Certification Report** UF Fiscal Year 2017-2018
July 1, 2017 – June 30, 2018



## **Table of Contents**

Transmittal Document CTRB Bond Compliance	3
Executive Summary	3
Changes in Method from Year 4	4
Issues Going Forward	4
CTRB Compliance Report	5
General Background	5
Definitions	5
CTR Building Occupants and Users	6
Space as Related to Program Activity	6
Grant and Research Project Activity Types	7
The Compliance Review Process	8
CTRB Bond Certification Process	9
Diagram 1. Map of Revenue Zones for CTRB Bond Certification	9
Sponsored Research (Red Zone)	9
Data Collection Overview	9
Algorithm	10
Other Support (Blue Zone)	11
Data Collection Overview	11
Blue Zone 2 Algorithm	11
Clinical Research Center (Black Zone)	12
CTRB Bond Certification Results Summary	12
Table Set 1. Annual Summary data by Zone (2014-2018)	12
Table 2. Square footage by building occupant department (2018)	13
Table 3. Blue Zones 1 & 2 Fund Code Classification	14
Table 4. Safe Harbor Designation Summary from DSP (2018)	16
Table 5. Research Revenue by Prime Sponsor Type (2018)	16
Table 6. Summary of Survey Results by Contract Principal Investigator (2018)	17

## **Transmittal Document CTRB Bond Compliance**

July 31, 2018

### **Executive Summary**

Attached please find the report required by the Tax Exempt Bond financing agreement for the Clinical Trials Research Building (CTRB) dated March 31, 2011. This is the fifth report in a cumulative 20 year series of reports to demonstrate that the vast preponderance (90%) of the activity of the CTRB is dedicated to public benefit.

This report is the summary of the annual process to define and categorize "research revenues" accumulated through the use of the CTRB and classify the benefits derived as "good" (public benefit) or "bad" (private benefit). Executives from the University Health Science Center, Legal Affairs and Bond Compliance were involved as well as senior scientists and department and institute managers with activities in the building. Note that the revenue was calculated in four zones were then combined into an overall amount. The process and definitions are fully described in body of the report.

By the method described in the report, we calculated that the cumulative ratio of good (public) benefit to total "research revenue" for the year 2014-2018 years to be 90.2%, the percentage of good use for each year is summarized in the table below. This cumulative percentage good use is exceeds the 90% specified in the Tax Exempt Bond financing agreement for the Clinical and Translational Research Building.

#### **Cumulative Overall Research Revenue and Classification**

	Total Research Revenue	Amount in CTRB	Good Use	Bad Use	% Good Use
2014 Overall	\$96,719,030	\$43,404,982	\$38,849,593	\$4,555,390	89.5%
2015 Overall	\$151,280,706	\$70,139,419	\$63,753,083	\$6,386,336	90.9%
2016 Overall	\$168,767,359	\$82,959,788	\$74,013,059	\$8,946,729	89.2%
2017 Overall	\$212,777,908	\$148,690,020	\$134,025,899	\$14,664,120	90.1%
2018 Overall	\$257,701,515	\$163,323,650	\$147,898,341	\$15,425,308	90.6%
Cumulative Total for 2014-2018	\$887,246,518	\$508,517,859	\$458,539,976	\$49,977,883	90.2%

2018	Total Research Revenue	Amount in CTRB	Good Use	Bad Use	% Good Use
Red Zone: Sponsored Research	\$243,891,313	\$154,772,738	\$141,755,175	\$13,017,563	91.6%
Blue Zone 1: High Occupancy Depts	\$8,232,059	\$6,373,401	\$4,573,264	\$1,800,137	71.8%
Blue Zone 2: Low Occupancy Depts	\$4,483,748	\$1,083,116	\$941,503	\$141,613	86.9%
Black Zone: Clinical Research Center	\$1,094,395	\$1,094,395	\$628,400	\$465,995	57.4%
Total	\$257,701,515	\$163,323,650	\$147,898,341	\$15,425,308	90.6%

### **Changes in Method from Year 4**

There were no changes in method from year 4.

#### **Issues Going Forward**

The collection of the space survey for UF has an official deadline in the fall of each year. This year the staff responsible for space data collection were instructed by the senior management of UFHealth to complete the space data collection for the CTRB by May 31, 2018. The data used in this report were extracted on June 1, 2018 from the space survey database, allowing us to start and complete the bond certification process by the reporting deadline. We should continue to require that the space survey for the CTRB North Wing be completed by June 4 or earlier to meet the Bond Compliance Reporting deadline.

## **CTRB Compliance Report**

### **General Background**

The University of Florida Clinical and Translational Research Building (CTRB) serves as the *headquarters* for clinical and translational science at UF. It is home to the Clinical and Translational Science Institute (CTSI) which conducts on-site research and is also the hub of a statewide network that aims to bring "the benefits of research to more than 9 million patients in all of Florida's 67 counties" (see <a href="CTSI">CTSI</a> website).

The north wing of the CTRB was funded with tax-exempt bonds. The bonds have specific covenants requiring that the vast preponderance of "research revenue" generated through the use of the building over the 20-year life of the bonds be in the clear public benefit. More precisely the ratio of "qualified research revenue" (that is clearly in the public benefit) to total research revenue must exceed 90%. In addition to this qualified research condition, there are restrictions on other purely commercial activities such as bookstores or kiosks.

Note: Though the north wing of the CTRB physically adjoins with the south wing, home to the UF Institute on Aging headquarters, the south wing was constructed with a NIH grant and is specifically excluded from any CTRB covenants pertaining to the north wing.

### **Definitions**

**Research revenue** is defined as revenue from "research arrangements" ("contracts, grants, etc. with a state or local governmental unit, a Federal Sponsor or any other third party"). The term "research revenue" is not widely used within academic medicine. Interpreted broadly, it was construed to subsume several more common concepts such as research funding, research awards and research support. It may also subsume all or part of traditional categories, such as cost recoveries and gifts.

Note: The broadest (most conservative) definition of research revenue has been used in the report, which specifically includes grants and contracts that are routed through the Office of Research, and general support for other research activities that are not funded through an "official" contract or grant.

**Basic Research** The compliance definition of "basic research" includes any original investigation for the advancement of scientific knowledge not having a specific commercial objective. This very broad definition includes clinical research and other research activities that do not have a specific commercial objective.

Note: The broadest (most conservative) definition of basic research has been used in the report to include all research activities – translational, clinical and health services.

**Laboratories** The term "laboratories" which is frequently used in the compliance agreement is difficult to precisely apply to research involving human subjects where a relatively small proportion of the research activity is conducted in "wet labs" and much work requires both clinical and research venues. Translational research is frequently conducted in multiple venues in multiple buildings and even at

multiple universities. The rate limiting factor in clinical research is often access to appropriate subjects rather than access to highly capitalized laboratory facilities.

Note: The broadest (most conservative) definition of laboratories has been used in the report and includes the Clinical Research Center, an "auxiliary" that may be considered analogous to a core laboratory in a wet lab setting and certain support units such as Biostatistics.

### **CTR Building Occupants and Users**

Four general levels of occupants and users have been included in the report.

Major Building Tenants: Research institutes and university departments that are headquartered in the CTRB and have substantial programmatic presence in the building. These are the Clinical and Translational Science Institute (12,849 square feet), the Department of Epidemiology (6,148 square feet) and the Departments of Biostatistics (4,821 square feet). These occupants are specifically referenced in the compliance agreement. (see Table 2)

**Minor Building Tenants**: These include the research groups specifically referenced in the compliance agreement. Research groups are not in themselves organizational units of the university, but they are: - members of university departments that are not headquartered in the CTRB, -have significant translational research activities in the CTRB, and -collaborate with other CTRB occupants. The Department of Health Outcomes and Policy, which is headquartered outside the CTRB, is the largest of this group, and the Department of Medicine has several of these research groups or "colonies".

**Occasional and infrequent users:** These are individual investigators and research associates who are not included as members of major or minor tenants but who may use services of the Clinical Research Center (CRC) or other building occupants. In nearly all cases these are university faculty and staff.

**Clinical Research Center (CRC):** This special category was created to consider the CRC located on the first floor which is a CTSI service auxiliary that recovers the preponderance of its direct costs through transfer payments and fees charged to facility users.

Note: The same compliance standard was used for each level of user or building occupant, but data collection methods were adapted to their unique circumstances.

### **Space as Related to Program Activity**

Grants and projects activity are often not restricted to individual spaces or buildings, the actual conduct of the research studies can occur across a wide number of institutions. Many projects and programs have substantial activities that reach far beyond the CTRB and even the campus. In some instances, CTRB occupants and users may be at the "project level", such as a biostatistician supporting a grant, so only a small portion of the overall activity related to its parent grant or contract occurs in the CTRB. In other instances, the large majority of the grant activity occurs in the CTRB.

Note: The university's annual space survey interviews building occupants and users of individual spaces within the building and details the projects, grants and other forms of support that are associated with

each space. The CTRB report includes only activity from grants and projects identified in the space survey as having <u>activity in the CTRB</u>.

### **Grant and Research Project Activity Types**

Financial accounting structures may be different depending on the formality of the research project and the external reporting requirements. The compliance review considered four general categories of grants and research activity.

#### **Extramural Grants and Contracts**

All major externally funded grants and contracts are identified in the UFirst Awards Database and include contact information for the Award Principle Investigators (PI). Awards can contain one or more projects.

Note: Each Award PI (n=114) was surveyed about the Awards (n=318) whose related projects were identified in the space survey. The award PI was asked to estimate the proportion of the overall award activity that occurred in the CTRB between 7/1/2017 and 6/30/2018. This ratio was applied to the overall award to determine the amount of research revenue appropriately associated with the CTRB..

#### **Other Defined Research Projects**

These may be sponsored by foundation, individuals, businesses associations or others.

Note: Depending on the financial structure, these activities could be treated as major grants (above) or as projects that were accounted through a grouping of associated "fund codes" that identify streams of support that could be characterized as revenue. Deliberate attention was paid to avoid any double counting of revenue or support.

#### **Departmentally Sponsored Research**

These may be startup funding for new investigators, seed funding during grant development or other activities deemed to foster research or the growth of research capability that is directly associated with an individual researcher or research group.

Note: These activities are not well compartmentalized in the accounting system and were categorized by groupings of fund codes.

#### **General Research Support Activities and Services**

These activities may provide necessary professional skills, facilities, software or a wide range of general support for researchers, research grants and the "research environment". In most cases "fund codes" were used to characterize support.

Note: These activities were reported from departmental records and may include all direct support for programs completely housed in the CTRB.

### **The Compliance Review Process**

The compliance review process involved three distinct phases: identification, apportionment and disclosure.

#### 1) Identification of CTRB activities

Building use was identified in concert with the university's annual space survey.

Note: All projects with <u>any</u> CTRB involvement were identified during the space survey. Activities that could be directly identified with a principle investigator were treated as major grants and subject to the principle Investigator survey. Research activities that are not counted as "sponsored research" in the university's space survey were included in the department review process. These two methods were checked to avoid duplication of accounting and the results were combined in the final compliance accounting.

#### 2) Apportionment of Activity

Apportionment is the basis by which research activity is divided into the CTRB and non CTRB portions. Three basic approaches to apportionment were needed to complete the compliance review process: grant activity apportionment (PI), programmatic apportionment (Major Tenants and CRC) and individual effort apportionment (Minor Tenants and infrequent users).


Note: Since apportionment requires judgment calls, the responsible individual with "the best view" of the distribution of activity in each situation was interviewed. For major grants the PI was surveyed directly though in some cases the grant administrator or project PI was allowed to submit a proxy response. Department heads or administrators were required to complete budget worksheets for revenue identified as general support. In a few instances of minor occupants and infrequent users, nonsponsored research categories, such as "department research" and "other support activities", from the space survey were examined to determine the best basis for CTRB use. (See table 6).

#### 3) Disclosure and Safe Harbors

The UF Office of Clinical Research applied the Stanford University safe harbor rules to review and classify UF intellectual property right for funded research. Fund codes were used to classify the non-sponsored research activities as "good" or "bad" use.

### **CTRB Bond Certification Process**

Diagram 1. Map of Revenue Zones for CTRB Bond Certification



### **Sponsored Research (Red Zone)**

#### **Data Collection Overview**

- Obtain list of PeopleSoft (PS) project numbers and corresponding CTRB room numbers reported in CTRB space survey
- Merge PS project numbers with UFirst Awards History database to obtain additional data fields such as award amount, Award PI, etc.
- Merge Award PI UFID to UF Directory to obtain Contract PI email and other contact information.
- Map PS project from space survey to the related contracts (aka "award") level and load contract information to Qualtrics survey
- The set of awards was provided to the Office of Clinical Research. This office reviewed each contact and provided a determination of "Good" or "Bad" use.

- Field Qualtrics survey to collect the percentage of Award Activity occurring in the North wing of the CTRB from the Award PI.
- Apply "% activity in CTRB" to total award amount (less sub-contracts) to calculate qualified research revenue for sponsored activities in CTRB (i.e. grants or contracts with a PS project number reported in space survey)

### **Algorithm**

**Total Award:** Amount in Dollars Awarded for the Fiscal Year Source: UF Office of Research – UFirst Awards History Data

**PctCTRB:** Percentage of Award Activity in the CTRB Source: Principal Investigator Qualtrics Survey

CTRB\_Activity\_Amount: Amount in Dollars of Activity in CTRB

Calculated: AwardAmt \* PctCTRB

**Safe\_Harbor\_Use:** 1=meets requirements for "Good Use", 0=Otherwise

Source: Contract Review by Office of Research

CTRB\_Good\_Use: Amount in Dollars of "Good Use" Activity in CTRB

Calculated: CTRB\_Activity\_Amount \* Safe\_Harbor\_Use

Good Use Proportion: Percentage of CTRB activity assigned to "Good Use"

Calculated: CTRB\_Good\_Use / CTRB\_Activity\_Amount

Good\_Use Proportion: (Total\_Award ) \* PctCTRB \* Safe\_Harbor\_Use

(Total\_Award) \* PctCTRB

### Other Support (Blue Zone)

#### **Data Collection Overview**

- Purpose: identify additional support that should count as "qualified research revenue" but is not assigned a PeopleSoft project number from the Office of Research (i.e. 171 funds)
- Data process divided into two groups based on square footage (see table 2):
  - Blue Zone 1: Departments that occupy >14% of the north wing will review department operating budget for the reporting year and submit the following in an excel file:
    - Identify support for research activity that is not funded by grants or contracts (i.e. not included in Red Zone)
    - Apportion the % of activity in the building
    - Apply % activity to budgeted amount (this is amount that counts as QRR)
    - Classify good vs. bad using fund code definitions (see table 3)
  - Blue Zone 2: Departments that occupy <9% of the north wing will use "department research" and "OSA" categories in the space survey to:
    - Use DR and OSA % as proxy for % activity in the building
    - Use primary room occupant earnings as proxy for qualified research revenue
    - Classify good vs. bad using fund code definitions (see table 3)

### **Blue Zone 2 Algorithm**

Salary Paid: Amount paid in Salary for time period

Fringe Paid: Amount of Fringe Benefits paid in time period

Fund\_Mask: 1 if Fund Code is "Good" Use, 0 otherwise

Omit\_Rec: 1 if record is to be Omitted (O Otherwise) Added to remove funds counted in RedZone.

**DR\_11:** Proportion of Payment attributable to department research Source: UF Payroll File

**OSA\_17:** Proportion of Payment attributable to other sponsored activities Source: UF Payroll File

**Qualified Total Paid:** Amount of Salary and Fringe Paid classified as Qualified Revenue Calculated (Salary\_Paid+Fringe\_Paid) X (DR\_11\_1 + OSA\_17\_1)

Qualified Good: Total Salary & Fringe Paid where Fund\_Mask=1 (Good Use Funds)

Calculated: Qualified Total Paid X Fund\_Mask

**Proportion of Good Use:** Percentage of Activity in CTRB Attributed to "Good" Use Calculated: **Qualified Good / Qualified Total Paid** 

Using only records where Omit Rec=0, calculate:

(Salary\_Paid + Fringe\_Paid)\*(DR\_11 + OSA\_17)\*Fund\_Mask

### **Clinical Research Center (Black Zone)**

Revenues generated from Clinical Research Center (CRC) that are not identified in the "grants and contracts" or "other support" data collection efforts are also are classified as Good / Bad Use based on Sponsor type or determination by the Division of Sponsored programs. Investigational Pharmacy Service previously reported as the "Olive Zone" are now included in the CRC (Black Zone) revenues.

## **CTRB Bond Certification Results Summary**

**Table Set 1. Annual Summary data by Zone (2014-2018)** 

Qualified Research Revenue 2014					
2014	Total Research Revenue	Amount in CTRB	Good Use	Bad Use	% Good Use
Red Zone: Sponsored Research	\$89,392,364	\$39,446,528	\$35,591,687	\$3,854,841	90.2%
Blue Zone 1: High Occupancy Depts	\$4,822,880	\$3,192,551	\$2,769,644	\$422,908	86.8%
Blue Zone 2: Low Occupancy Depts	\$2,161,203	\$423,320	\$379,386	\$43,934	89.6%
Black Zone: Clinical Research Center	\$288,598	\$288,598	\$107,611	\$180,987	37.3%
Olive Zone: Shands Pharmacy	\$53,985	\$53,985	\$1,265	\$52,720	2.3%
Total	\$96 719 030	\$43,404,982	\$38 849 593	\$4 555 390	89 5%

#### **Qualified Research Revenue 2015** 2015 Total Research Revenue Amount in CTRB Good Use Bad Use % Good Use \$65,292,091 \$59,736,691 \$5,555,400 91.5% Red Zone: Sponsored Research \$141,554,852 \$6,074,849 \$500,936 86.2% Blue Zone 1: High Occupancy Depts \$3,632,069 \$3,131,134 Blue Zone 2: Low Occupancy Depts \$3,065,612 \$629,866 \$577,393 \$52,472 91.7% Black Zone: Clinical Research Center \$507,078 \$507,078 \$300,937 \$206,141 59.3% Olive Zone: Shands Pharmacy \$78,315 \$78,315 \$6,928 \$71,387 8.8% Total \$151,280,706 \$70,139,419 \$63,753,083 \$6,386,336 90.9%

Qualified Research Revenue 2016					
2016	Total Research Revenue	Amount in CTRB	Good Use	Bad Use	% Good Use
Red Zone: Sponsored Research	\$154,489,936	\$75,903,820	\$67,923,930	\$7,979,890	89.5%
Blue Zone 1: High Occupancy Depts	\$8,463,710	\$5,986,474	\$5,376,971	\$609,503	89.8%
Blue Zone 2: Low Occupancy Depts	\$5,062,469	\$318,250	\$306,819	\$11,432	96.4%
Black Zone: Clinical Research Center	\$751,244	\$751,244	\$405,339	\$345,904	54.0%
Total	\$168,767,359	\$82,959,788	\$74,013,059	\$8,946,729	89.2%

### **Qualified Research Revenue 2017**

2017	Total Research Revenue	Amount in CTRB	Good Use	Bad Use	% Good Use
Red Zone: Sponsored Research	\$197,803,469	\$140,143,298	\$126,884,664	\$13,258,634	90.5%
Blue Zone 1: High Occupancy Depts	\$10,049,302	\$6,430,362	\$5,548,556	\$881,806	86.3%
Blue Zone 2: Low Occupancy Depts	\$3,890,681	\$1,081,903	\$991,307	\$90,596	91.6%
Black Zone: Clinical Research Center	\$1,034,456	\$1,034,456	\$601,372	\$433,084	58.1%
Total	\$212,777,908	\$148,690,020	\$134,025,899	\$14,664,120	90.1%

2018	Total Research Revenue	Amount in CTRB	Good Use	Bad Use	% Good Use
Red Zone: Sponsored Research	\$243,891,313	\$154,772,738	\$141,755,175	\$13,017,563	91.6%
Blue Zone 1: High Occupancy Depts	\$8,232,059	\$6,373,401	\$4,573,264	\$1,800,137	71.8%
Blue Zone 2: Low Occupancy Depts	\$4,483,748	\$1,083,116	\$941,503	\$141,613	86.9%
Black Zone: Clinical Research Center	\$1,094,395	\$1,094,395	\$628,400	\$465,995	57.4%
Total	\$257,701,515	\$163,323,650	\$147,898,341	\$15,425,308	90.6%

 Table 2. Square footage by building occupant department (2018)

Department	Area (square feet)	Percent of CTRB North	Occupancy Type	Zone
MD-CTSI	12,849	35.2%	Major	Blue1
PHHP-COM EPIDEMIOLOGY	6,148	16.8%	Major	Blue1
PHHP-COM BIOSTATISTICS	4,821	13.2%	Major	Blue1
MD-HEALTH OUTCOMES AND				
POLICY	4,642	12.7%	Major	Blue2
HP-PHYSICAL THERAPY	2,222	6.1%	Minor	Blue2
MD-MEDICINE	2,160	5.9%	Minor	Blue2
MD-PEDIATRICS	1,794	4.9%	Minor	Blue2
DN-COMMITY BASED PROGRAMS	894	2.5%	Minor	Blue2
PPD-OPER HC SYSTEMS	669	1.8%	Minor	Blue2
PPD-OPERATIONS HC-ADMIN	164	0.5%	Minor	Blue2
PH-PHARMTHERAPY TRNSL RSCH	151	0.4%	Minor	Blue2

Table 3. Blue Zones 1 & 2 Fund Code Classification

Fund_Codes	Fund Code Description	Good/Bad?
101	E&G-GEN REV - MAIN CAMPUS	GOOD
	State Appropriations	
102	E&G-GEN REV – HSC	GOOD
	State Appropriations	
106	E&G-GEN REV UF ON-LINE	GOOD
	State Appropriations – UF Online	
107	E&G-GEN REV-PREEMINENCE	GOOD
	This fund will be used to budget and track expenditures from	
	State Preeminence funds.	
143	AUX - DOCE FUND	GOOD
	Division of Continuing Education (DCE)	
149	AUX - OTHER FUNDS	BAD
	Current unrestricted fund used to account for sales of goods	
	and services to faculty, staff and students.	
151	AUX - WORKING CAPITAL TR FD	BAD
	Current unrestricted fund used to account for the auxiliary-	
	related financial transactions of the Physical Plant Division.	
171	TFRS FR COMPONENTS	GOOD
	A current restricted fund used to account for monies	
	received from the University of Florida's component units	
	(e.g DSOs).	
175	UF STRATEGIC FUND NONRESEARCH	BAD
	This fund was established to support strategic initiatives that	
	are not restricted for research.	
179	OTHER MISC DONATIONS	GOOD
	A current unrestricted fund used to record incidental	
	revenues from various unrestricted sources. There are no	
	external requirements placed on the money in this fund.	
182	IFAS - EXT SVC INCIDENTAL TF	BAD
	A current unrestricted fund established to support the	
	Extension function of UF/IFAS. Revenues are from the sale of	
	Extension publications, products, and programs, and fees for	
101	diagnostic testing.	
191	STUDENT GOVT FUNDS	BAD
	A current unrestricted fund established for the collection of	
404	student activity fees.	6000
194	PAYROLL FUND  A 'halding' fund used by University Payrell and University	GOOD
	A 'holding' fund used by University Payroll and University	
	Tax Services, to process payroll and tax related transactions	
	that cannot be immediately posted to the appropriate cost	
	center. These deposits and expenses are distributed to the	
204	appropriate cost center after they are reconciled.	DEMOVE
201	C&G - FEDERAL RESTRICTED	REMOVE

Fund_Codes	Fund Code Description	Good/Bad?
	A restricted fund used to account for Federal and Federal	
	flow thru contracts and grants related to research, training,	
	or other sponsored activities.	
209	C&G - OTHER RESTRICTED	REMOVE
	A restricted fund used to record contracts and grants from	
	State, corporate, and private sources for research, training,	
	and other sponsored activities.	
211	C&G - RETURNED OVERHEAD	GOOD
	A restricted fund used to accumulate and manage all the	
	earned overhead from research projects. These funds are to	
	be used only in support of other research or sponsored	
	training programs, as directed in Section 1004.22(5), Florida	
	Statutes.	
212	C&G - RESIDUAL FUNDS	GOOD
	A restricted fund used to record money from miscellaneous	
	donors and earned residuals from research projects. These	
	funds are to be used only in support of other research or	
	sponsored training programs, as directed in Section	
	1004.22(5), Florida Statutes and by UF Policy.	
213	UFRF ALLOCATIONS	GOOD
	A restricted fund used to accumulate and manage deposits	
	from the direct support organization, UF Research	
	Foundation (UFRF). These funds are restricted and are to be	
	used in support of other research or sponsored training	
	programs, as directed by UFRF.	
214	C&G NON FED CLINICAL TRIALS	BAD
	The C&G Non Fed Clinical Trials fund is a restricted fund that	
	was established to support the University's Industry	
	Sponsored Clinical Trial Business.	
221	IFAS - EXP STAT FEDERAL TF	GOOD
	A restricted fund used to record money from the Hatch Act	
	Federal Appropriation. These funds are restricted to the	
	research function	
279	RESTRICTED INCIDENTAL FUND	GOOD
	A current restricted fund to place incidental revenues that	
	are restricted to a specific department or purpose.	

 Table 4. Safe Harbor Designation Summary from DSP (2018)

Prime Sponsor Type	Good Use	Bad Use	Total
Federal Agencies	149	0	149
Corporations/CompanyForProfit	37	69	106
Non Profit Organizations	33	4	37
University of Florida	14	0	14
UF DSO and Related HSC Affilia	10	0	10
Florida Government	4	0	4
Non-Florida Government	2	0	2
Miscellaneous	0	1	1
University of FlaFoundation	1	0	1
Total Number of Awards	250	74	324

 Table 5. Research Revenue by Prime Sponsor Type (2018)

Prime Sponsor Type	Total Research	CTRB Research	Good Research	Bad Research
Printe Sponsor Type	Revenue	Revenue	Revenue	Revenue
Federal Agencies	\$114,982,127	\$50,804,592	\$50,804,592	\$0
Corporations/CompanyForProfit	\$50,082,882	\$45,669,746	\$36,682,923	\$8,986,823
University of Florida	\$37,439,786	\$36,591,404	\$36,591,404	\$0
Non Profit Organizations	\$31,151,906	\$16,343,788	\$12,315,548	\$4,028,240
Florida Government	\$4,642,708	\$1,615,998	\$1,615,998	\$0
UF DSO and Related HSC Affilia	\$4,577,287	\$3,301,407	\$3,301,407	\$0
Non-Florida Government	\$979,862	\$440,078	\$440,078	\$0
University of FlaFoundation	\$32,254	\$3,225	\$3,225	\$0
Miscellaneous	\$2,500	\$2,500	\$0	\$2,500
Total	\$243,891,313	\$154,772,738	\$141,755,175	\$13,017,563

Table 6. Summary of Survey Results by Contract Principal Investigator (2018)

Contract PI Name	Number of	Amount in	CTRB Good	CTRB Bad	Percent
	Awards	CTRB	Revenue	Revenue	Good in
					CTRB
Nelson, David	25	\$82,348,538	\$81,635,832	\$712,706	99%
Shenkman, Elizabeth	19	\$20,343,514	\$16,316,578	\$4,026,936	80%
Vandenborne, Krista	13	\$10,031,940	\$5,979,326	\$4,052,614	60%
Fillingim, Roger	8	\$6,633,245	\$6,633,245	\$0	100%
Haller, Michael	9	\$4,361,231	\$4,322,408	\$38,823	99%
Schatz, Desmond	12	\$3,347,075	\$3,334,794	\$12,281	100%
Byrne, Barry	22	\$2,334,169	\$227,812	\$2,106,357	10%
Cottler, Linda	6	\$2,003,282	\$1,791,025	\$212,257	89%
Riley, Joseph	3	\$1,888,632	\$1,888,632	\$0	100%
Gurka, Matthew	1	\$1,580,281	\$1,580,281	\$0	100%
Golde, Todd	1	\$1,429,354	\$1,429,354	\$0	100%
Chen, Xinguang	2	\$1,386,280	\$1,386,280	\$0	100%
Zhao, Jinying	4	\$1,338,149	\$1,338,149	\$0	100%
Cook, Robert	9	\$1,307,941	\$1,307,941	\$0	100%
Delcher, Philip	8	\$1,176,862	\$1,174,362	\$2,500	100%
Muller, Keith	3	\$1,136,531	\$1,136,531	\$0	100%
Yost, Richard	3	\$970,342	\$970,342	\$0	100%
Walter, Glenn	2	\$896,019	\$896,019	\$0	100%
Maldonado Molina, Mildred	4	\$829,501	\$829,501	\$0	100%
Prosperi, Mattia	7	\$691,652	\$691,652	\$0	100%
Morelli, Giuseppe	13	\$682,811	\$198,549	\$484,262	29%
Firpi-Morell, Roberto	10	\$666,889	\$124,262	\$542,627	19%
Corti, Manuela	7	\$612,081	\$612,081	\$0	100%
Cusi, Kenneth	7	\$598,160	\$130,324	\$467,836	22%
Datta, Somnath	3	\$519,490	\$519,490	\$0	100%
Shaddox, Luciana	1	\$477,025	\$477,025	\$0	100%
Vogel, Walter	3	\$420,071	\$420,071	\$0	100%
Hogan, William	3	\$411,680	\$411,680	\$0	100%
Staras, Stephanie	1	\$351,232	\$351,232	\$0	100%
Campbell Thompson, Martha	1	\$348,844	\$348,844	\$0	100%
Sweeney, Hugh	1	\$284,239	\$284,239	\$0	100%
Brumback, Babette	1	\$281,882	\$281,882	\$0	100%
Smith, Barbara	5	\$276,672	\$185,579	\$91,093	67%
Conrad, Kirk	1	\$242,345	\$242,345	\$0	100%
Okunieff, Paul	1	\$220,214	\$220,214	\$0	100%
Cheng, Ting-Yuan	1	\$176,336	\$176,336	\$0	100%
Johnson, Julie	2	\$169,784	\$169,784	\$0	100%

Contract PI Name	Number of	Amount in	CTRB Good	CTRB Bad	Percent
	Awards	CTRB	Revenue	Revenue	Good in
					CTRB
Bishop, Mark	1	\$149,985	\$149,985	\$0	100%
Licht, Jonathan	4	\$137,414	\$137,414	\$0	100%
Forbes, Sean	1	\$125,804	\$125,804	\$0	100%
Mai, Volker	2	\$125,339	\$106,907	\$18,432	85%
Cavallari, Larisa	1	\$121,118	\$121,118	\$0	100%
Qiu, Peihua	1	\$120,001	\$120,001	\$0	100%
Modave, Francois	1	\$114,375	\$114,375	\$0	100%
Pearson, Thomas	1	\$112,241	\$112,241	\$0	100%
Wu, Samuel	1	\$93,503	\$93,503	\$0	100%
Clark, Virginia	5	\$80,144	\$39,291	\$40,853	49%
Hu, Hui	1	\$72,307	\$72,307	\$0	100%
Gurka, Kelly	2	\$66,449	\$66,449	\$0	100%
Fuller, David	1	\$65,168	\$65,168	\$0	100%
Jolley, Christopher	2	\$63,890	\$0	\$63,890	0%
Brady, Linda	1	\$56,504	\$56,504	\$0	100%
Terry, Ellen	1	\$47,898	\$47,898	\$0	100%
Gonzalez-Peralta, Regino	5	\$45,913	\$5,184	\$40,729	11%
Subramony, Sankarasubramon	2	\$40,667	\$0	\$40,667	0%
Moldawer, Lyle	1	\$25,500	\$25,500	\$0	100%
Heldermon, Coy	2	\$24,554	\$0	\$24,554	0%
McCormack, Wayne	1	\$22,458	\$22,458	\$0	100%
Morris, John	2	\$21,435	\$21,435	\$0	100%
Lawrence, Robert	1	\$20,591	\$0	\$20,591	0%
Forsmark, Christopher	1	\$19,892	\$19,892	\$0	100%
Ross, Kathryn	1	\$19,304	\$19,304	\$0	100%
Kertes, Darlene	1	\$18,907	\$18,907	\$0	100%
Striley, Catherine	2	\$18,097	\$18,097	\$0	100%
Neu, Josef	1	\$15,826	\$15,826	\$0	100%
Wang, Gary	2	\$15,001	\$9,267	\$5,734	62%
Woods, Adam	2	\$11,243	\$11,243	\$0	100%
Brakenridge, Scott	1	\$11,162	\$11,162	\$0	100%
Kang, Peter	1	\$10,517	\$0	\$10,517	0%
Moore, Frederick	2	\$9,347	\$9,347	\$0	100%
Kairalla, John	1	\$8,885	\$8,885	\$0	100%
Jeong, Kwang	1	\$8,749	\$8,749	\$0	100%
Silverstein, Janet	1	\$8,736	\$8,736	\$0	100%
Tighe, Patrick	1	\$8,296	\$8,296	\$0	100%
Ding, Mingzhou	1	\$6,326	\$6,326	\$0	100%
Salemi, Marco	1	\$4,915	\$4,915	\$0	100%

Contract PI Name	Number of	Amount in	CTRB Good	CTRB Bad	Percent
	Awards	CTRB	Revenue	Revenue	Good in
					CTRB
Moseley, Ray	1	\$4,383	\$4,383	\$0	100%
Price, Catherine	2	\$3,873	\$3,873	\$0	100%
Cabrera, Roniel	2	\$3,398	\$3,398	\$0	100%
Lucero, Robert	1	\$3,333	\$3,333	\$0	100%
Atkinson, Mark	2	\$3,218	\$3,218	\$0	100%
Chen, Zhiguo	1	\$3,009	\$3,009	\$0	100%
Henken, Robin	1	\$2,984	\$2,984	\$0	100%
Pepine, Carl	1	\$2,967	\$2,967	\$0	100%
Wang, Yan	1	\$2,779	\$2,779	\$0	100%
Raup-Krieger, Janice	1	\$2,748	\$2,748	\$0	100%
Vaillancourt, David	1	\$2,114	\$2,114	\$0	100%
Cohen, Ronald	2	\$2,015	\$2,015	\$0	100%
Karst, Stephanie	1	\$1,905	\$1,905	\$0	100%
Okun, Michael	1	\$1,728	\$1,728	\$0	100%
Leeman, Robert	1	\$1,643	\$1,643	\$0	100%
Winter, Sandra	1	\$1,581	\$1,581	\$0	100%
Morris, Heather	1	\$1,304	\$0	\$1,304	0%
Li, Qiuhong	1	\$1,182	\$1,182	\$0	100%
Bihorac, Azra	1	\$1,127	\$1,127	\$0	100%
Stacpoole, Peter	1	\$528	\$528	\$0	100%
Walker, Ashby	1	\$495	\$495	\$0	100%
Nittrouer, Susan	1	\$447	\$447	\$0	100%
Khoshbouei, Habibeh	1	\$432	\$432	\$0	100%
Christou, Evangelos	1	\$358	\$358	\$0	100%
Patten, Carolynn	1	\$345	\$345	\$0	100%
Odedina, Folakemi	1	\$87	\$87	\$0	100%
Allen, Kyle	1	\$0	\$0	\$0	
Cardel, Michelle	1	\$0	\$0	\$0	
Efron, Philip	1	\$0	\$0	\$0	
Ferris, Daniel	1	\$0	\$0	\$0	
Hegland, Karen	1	\$0	\$0	\$0	
Martens, Jeffrey	1	\$0	\$0	\$0	
Martin, Anatole	1	\$0	\$0	\$0	
Nixon, Sara	1	\$0	\$0	\$0	
Ploetz, Randy	1	\$0	\$0	\$0	
Rivkees, Scott	1	\$0	\$0	\$0	
Sonke, Jill	1	\$0	\$0	\$0	
Zarrinpar, Ali	1	\$0	\$0	\$0	